MTOR: On target for novel therapeutic strategies in the nervous system

Trends in Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 51-60

  Maiese, Kenneth ^a,b   Chong, Zhao Zhong ^a   Shang, Yan Chen ^a   Wang, Shaohui ^a  

^a New Jersey Health Sciences University   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Apoptosis; Autophagy; MTORC1 2; Neurodegeneration; Stem cells; Tuberous sclerosis

Indexed keywords

EVEROLIMUS; FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RHEB PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE; THREONINE;

ACTIN FILAMENT; ALZHEIMER DISEASE; APOPTOSIS; AUTOPHAGY; CELL CONTACT; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; DEGENERATIVE DISEASE; DRUG TARGETING; EPILEPSY; HUMAN; HUNTINGTON DISEASE LIKE SYNDROME; NERVOUS SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUBEROUS SCLEROSIS;

ANIMALS; APOPTOSIS; HUMANS; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STEM CELLS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84871721552     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.11.001     Document Type: Review

References (112)

1. Chong Z.Z., et al. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid. Med. Cell. Longev. 2010, 3:374-391.
2. Brown E.J., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
3. Heitman J., et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253:905-909.
4. Chong Z.Z., et al. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog. Neurobiol. 2012, 99:128-148.
5. Takahashi T., et al. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells 2000, 5:765-775.
6. Benjamin D., et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10:868-880.
7. Acosta-Jaquez H.A., et al. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol. Cell. Biol. 2009, 29:4308-4324.
8. Chiang G.G., Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 2005, 280:25485-25490.
9. Reynolds T.H., et al. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem. 2002, 277:17657-17662.
10. Soliman G.A., et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J. Biol. Chem. 2010, 285:7866-7879.
11. Wang L., et al. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J. Biol. Chem. 2009, 284:14693-14697.
12. Wang H., et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell. Signal. 2012, 24:17-24.
13. Chen E.J., Kaiser C.A. LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway. J. Cell Biol. 2003, 161:333-347.
14. Kim D.H., et al. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11:895-904.
15. Guertin D.A., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 2006, 11:859-871.
16. Peterson T.R., et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
17. Zhao Y., et al. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol. Cell 2011, 44:304-316.
18. Sarbassov D.D., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
19. Chen C.H., Sarbassov dos D. The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. J. Biol. Chem. 2011, 286:40386-40394.
20. Pearce L.R., et al. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem. J. 2011, 436:169-179.
21. Gingras A.C., et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12:502-513.
22. Lenz G., Avruch J. Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. J. Biol. Chem. 2005, 280:38121-38124.
23. Cota D., et al. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
24. Sarbassov D.D., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
25. Gulhati P., et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71:3246-3256.
26. Hernandez-Negrete I., et al. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J. Biol. Chem. 2007, 282:23708-23715.
27. Cai S.L., et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol. 2006, 173:279-289.
28. Huang J., et al. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 2008, 28:4104-4115.
29. Inoki K., et al. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
30. DeYoung M.P., et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008, 22:239-251.
31. Murakami M., et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 2004, 24:6710-6718.
32. Gangloff Y.G., et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 2004, 24:9508-9516.
33. Zhou J., et al. mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7840-7845.
34. Iriuchishima H., et al. Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7α overexpression. Blood 2011, 117:2373-2377.
35. Easley C.A., et al. mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cell. Reprogramm. 2010, 12:263-273.
36. Han J., et al. Mammalian target of rapamycin (mTOR) is involved in the neuronal differentiation of neural progenitors induced by insulin. Mol. Cell. Neurosci. 2008, 39:118-124.
37. Malagelada C., et al. RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J. Neurosci. 2011, 31:3186-3196.
38. Magri L., et al. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell 2011, 9:447-462.
39. Maiese K., et al. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.
40. Shang Y.C., et al. Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr. Neurovasc. Res. 2011, 8:270-285.
41. Kim J., et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J. Cell. Biochem. 2012, 113:220-228.
42. Miriuka S.G., et al. mTOR inhibition induces endothelial progenitor cell death. Am. J. Transplant. 2006, 6:2069-2079.
43. Sato A., et al. Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR. Neurosci. Lett. 2010, 470:115-120.
44. Maiese K., et al. The Wnt signaling pathway: aging gracefully as a protectionist?. Pharmacol. Ther. 2008, 118:58-81.
45. Inoki K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
46. Huang J., et al. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J. Clin. Invest. 2009, 119:3519-3529.
47. Chong Z.Z., et al. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol. 2005, 75:207-246.
48. Zengi A., et al. Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Exp. Clin. Endocrinol. Diabetes 2011, 119:467-471.
49. Vendelbo M.H., Nair K.S. Mitochondrial longevity pathways. Biochim. Biophys. Acta 2011, 1813:634-644.
50. Tupe R.S., et al. Dietary nicotinic acid supplementation improves hepatic zinc uptake and offers hepatoprotection against oxidative damage. Br. J. Nutr. 2011, 25:1-9.
51. Maiese K., et al. Oxidative stress: biomarkers and novel therapeutic pathways. Exp. Gerontol. 2010, 45:217-234.
52. Maiese K., et al. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin. Ther. Targets 2012, 16:1203-1214.
53. Louneva N., et al. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am. J. Pathol. 2008, 173:1488-1495.
54. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 2000, 166:29-43.
55. Canu N., et al. Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells. J. Neurochem. 2005, 92:1228-1242.
56. Qin A.P., et al. Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia. Autophagy 2010, 6:738-753.
57. Wang J.Y., et al. Severe global cerebral ischemia-induced programmed necrosis of hippocampal CA1 neurons in rat is prevented by 3-methyladenine: a widely used inhibitor of autophagy. J. Neuropathol. Exp. Neurol. 2011, 70:314-322.
58. Baba H., et al. Autophagy-mediated stress response in motor neuron after transient ischemia in rabbits. J. Vasc. Surg. 2009, 50:381-387.
59. Spencer B., et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 2009, 29:13578-13588.
60. Spilman P., et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e9979.
61. Jeong J.K., et al. Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neurosci. Res. 2012, 73:99-105.
62. Chen L., et al. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKα leading to apoptosis of neuronal cells. Lab. Invest. 2010, 90:762-773.
63. Wu X., et al. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J. Biol. Chem. 2004, 279:9167-9175.
64. Shang Y.C., et al. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 2012, 4:187-201.
65. Chong Z.Z., et al. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3β and nuclear factor-κB to foster endogenous microglial cell protection. Int. J. Mol. Med. 2007, 19:263-272.
66. Pastor M.D., et al. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J. Biol. Chem. 2009, 284:22067-22078.
67. Choi K.C., et al. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. J. Neurochem. 2010, 112:366-376.
68. Chong Z.Z., et al. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS ONE 2012, 7:e45456.
69. Nascimento E.B., et al. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell. Signal. 2010, 22:961-967.
70. Carayol N., et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12469-12474.
71. Luo S., Rubinsztein D.C. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ. 2010, 17:268-277.
72. Wang S., et al. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr. Neurovasc. Res. 2012, 9:89-99.
73. Le X.F., et al. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010, 116:4980-4990.
74. Salminen A., et al. AMP-activated protein kinase: a potential player in Alzheimer's disease. J. Neurochem. 2011, 118:460-474.
75. Yu L., et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465:942-946.
76. Rong Y., et al. Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7826-7831.
77. Jung C.H., et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 2009, 20:1992-2003.
78. Hosokawa N., et al. Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 2009, 5:973-979.
79. Slipczuk L., et al. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS ONE 2009, 4:e6007.
80. Griffin R.J., et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005, 93:105-117.
81. An W.L., et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 2003, 163:591-607.
82. Paccalin M., et al. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 22:320-326.
83. Ma T., et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e12845.
84. Lafay-Chebassier C., et al. mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J. Neurochem. 2005, 94:215-225.
85. Chano T., et al. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain Res. 2007, 1168:97-105.
86. Imai Y., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
87. Tain L.S., et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 2009, 12:1129-1135.
88. Malagelada C., et al. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 2006, 26:9996-10005.
89. Crews L., et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE 2010, 5:e9313.
90. Santini E., et al. Inhibition of mTOR signaling in Parkinson's disease prevents l-DOPA-induced dyskinesia. Sci. Signal. 2009, 2:ra36.
91. Berger Z., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15:433-442.
92. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
93. Floto R.A., et al. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 2007, 3:620-622.
94. Roscic A., et al. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem. 2011, 119:398-407.
95. Fox J.H., et al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol. Neurodegener. 2010, 5:26.
96. Hyrskyluoto A., et al. GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway. Exp. Cell Res. 2012, 318:33-42.
97. Holmes G.L., Stafstrom C.E. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 2007, 48:617-630.
98. Jozwiak J., et al. Fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mTOR pathway. Am. J. Dermatopathol. 2009, 31:68-70.
99. Waltereit R., et al. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J. Neurochem. 2006, 96:407-413.
100. Zeng L.H., et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008, 63:444-453.
101. Buckmaster P.S., et al. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci. 2009, 29:8259-8269.
102. Zeng L.H., et al. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 2009, 29:6964-6972.
103. Curran M.P. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr. Drugs 2012, 14:51-60.
104. Krueger D.A., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 2010, 363:1801-1811.
105. Pavel M.E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
106. Jin N., et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 2009, 94:4107-4112.
107. Gulhati P., et al. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis 2012, 33:1782-1790.
108. Mi R., et al. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. J. Genet. Genomics 2009, 36:355-361.
109. Fokas E., et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat. Oncol. 2012, 7:48.
110. Barrett D., et al. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs 2012, 14:299-316.
111. Grzybowska-Izydorczyk O., Smolewski P. mTOR kinase inhibitors as a treatment strategy in hematological malignancies. Future Med. Chem. 2012, 4:487-504.
112. Majumder S., et al. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS ONE 2011, 6:e25416.